MAPT and Alzheimer disease: A recent study of losartan also failed to show an impact on measures of brain atrophy in Alzheimer’s disease dementia.51 Although our study duration was for 1 year—a period which may not be long enough to detect structural brain changes, it is possible that ARBs affect the earlier molecular changes in Alzheimer’s disease such as amyloid dysregulation rather than latter mechanisms such as tau phosphorylation and brain or hippocampal atrophy.